Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) will host a conference call and live audio webcast on November 13, 2023, at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline. The call can be accessed by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international) with conference ID 13741831, or through the company's website. The webcast will be available on the website for 30 days after the call.

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline.

To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13741831, or click on this link and request a return call. The audio webcast can be accessed on the "Events and Presentations" page under the “Connect” tab of the Company's website at www.sperotherapeutics.com. The archived webcast will also be available on Spero's website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

• Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
  
  
• Tebipenem HBr is an investigational drug in the United States being developed for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not U.S. Food and Drug Administration (FDA)-approved.
  
  
• Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.
  

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and Strategic Finance
IR@sperotherapeutics.com
(617) 798-4039

Media Inquiries:
Lora Grassilli, Health Media Relations
Zeno Group
lora.grassilli@zenogroup.com
646-932-3735

When will Spero Therapeutics announce its third quarter 2023 financial results?

Spero Therapeutics will announce its third quarter 2023 financial results on November 13, 2023.

What time will the conference call and webcast take place?

The conference call and webcast will take place at 4:30 p.m. ET on November 13, 2023.

How can I access the conference call?

To access the conference call, dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13741831.

Can I listen to the conference call online?

Yes, the conference call can be accessed through the 'Events and Presentations' page under the 'Connect' tab of Spero Therapeutics' website at www.sperotherapeutics.com.

Will the webcast be available after the call?

Yes, the webcast will be available on Spero Therapeutics' website for 30 days following the call.